Allosteric inhibition abrogates dysregulated LFA-1 activation: Structural insight into mechanisms of diminished immunologic disease

Lymphocyte Function Associated antigen-1(LFA-1) has been implicated severely in the pathophysiology of inflammatory and autoimmune diseases. Its active and inactive conformations correlate with its diseased and non-diseased state respectively. This is determined by its degree of affinity for its intrinsic ligand (ICAM) at the active site and accompanying synergistic coordination at the α7 helix. This potentiates the role of inhibitors in disrupting this interaction allosterically. Herein, we present a first account of the structural dynamics which characterizes the inhibitory effect of a novel LFA-1 antagonist, Lifitegrast (SAR1118), upon binding to the I-domain allosteric site (IDAS) using molecular dynamics simulation. Findings from this study revealed that the inhibitor stabilized the closed conformation and reversed the open conformation to a low ICAM-affinity state (closed) as evidenced by the upward movement of the α7 helix and corresponding transitions at the active site. This in both cases favors the formation of the non-disease inactive form. Upon allosteric modulation, the inhibitor significantly restored protein stability, enhanced compactness and decreased residual fluctuation as crucial to its potency in the amelioration of immunological and inflammatory diseases which agrees with experimental studies. These findings could therefore serve as the basis for the exploration of the allosteric domain and its active site affinity modulation to aid the design of more specific and selective inhibitors.

[1]  Junichi Takagi,et al.  Locking in alternate conformations of the integrin αLβ2 I domain with disulfide bonds reveals functional relationships among integrin domains , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Ioan Andricioaei,et al.  Conversion between three conformational states of integrin I domains with a C-terminal pull spring studied with molecular dynamics. , 2004, Structure.

[3]  Richard W. Farndale,et al.  Structural Basis of Collagen Recognition by Integrin α2β1 , 2000, Cell.

[4]  Waldemar Kolanus,et al.  Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines , 2005, Nature Immunology.

[5]  S. Bodary,et al.  Competition between intercellular adhesion molecule‐1 and a small‐molecule antagonist for a common binding site on the αl subunit of lymphocyte function‐associated antigen‐1 , 2006, Protein science : a publication of the Protein Society.

[6]  M. Arkin,et al.  Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. , 2012, ACS medicinal chemistry letters.

[7]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[8]  R. Kriwacki,et al.  Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. , 1999, Journal of molecular biology.

[9]  Kremer,et al.  Molecular dynamics simulation for polymers in the presence of a heat bath. , 1986, Physical review. A, General physics.

[10]  Joerg Kallen,et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.

[11]  P. M. Davis,et al.  Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101)--a small molecule antagonist of leukocyte function associated antigen-1. , 2006, Journal of medicinal chemistry.

[12]  Y. Takada,et al.  Critical Threonine and Aspartic Acid Residues within the I Domains of β2 Integrins for Interactions with Intercellular Adhesion Molecule 1 (ICAM-1) and C3bi (*) , 1995, The Journal of Biological Chemistry.

[13]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[14]  Wei Yang,et al.  Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. , 2003, Immunity.

[15]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[16]  T. Springer,et al.  A Binding Interface on the I Domain of Lymphocyte Function-associated Antigen-1 (LFA-1) Required for Specific Interaction with Intercellular Adhesion Molecule 1 (ICAM-1) (*) , 1995, The Journal of Biological Chemistry.

[17]  Mohammad-Ali Javadi,et al.  Dry Eye Syndrome , 2009, Definitions.

[18]  M. Auer,et al.  Identification and X-ray Co-crystal Structure of a Small-Molecule Activator of LFA-1-ICAM-1 Binding , 2014, Angewandte Chemie.

[19]  C. Schaumburg,et al.  Dry Eye as a Mucosal Autoimmune Disease , 2013, International reviews of immunology.

[20]  E B Reilly,et al.  Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. , 2001, Journal of medicinal chemistry.

[21]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[22]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[23]  Nathalie Reuter,et al.  Measuring and comparing structural fluctuation patterns in large protein datasets , 2012, Bioinform..

[24]  N. S. Bogatyreva,et al.  [Radius of gyration is indicator of compactness of protein structure]. , 2008, Molekuliarnaia biologiia.

[25]  M. Arkin,et al.  Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[26]  T. Springer,et al.  Folding and Function of I Domain-deleted Mac-1 and Lymphocyte Function-associated Antigen-1* , 2000, The Journal of Biological Chemistry.

[27]  T. Ceska,et al.  Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry. , 2004, Biochemistry.

[28]  J. Barrish,et al.  Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold. , 2007, Bioorganic & medicinal chemistry letters.

[29]  E. Seifert,et al.  OriginPro 9.1: Scientific Data Analysis and Graphing Software - Software Review , 2014, J. Chem. Inf. Model..

[30]  Timothy A. Springer,et al.  Therapeutic antagonists and conformational regulation of integrin function , 2003, Nature Reviews Drug Discovery.

[31]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[32]  V. Perez,et al.  Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. , 2016, The ocular surface.

[33]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[34]  J. R. Huth,et al.  NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Shimaoka,et al.  Importance of force linkage in mechanochemistry of adhesion receptors. , 2006, Biochemistry.

[36]  C. Gahmberg.  Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. , 1997, Current opinion in cell biology.

[37]  Thean Chor Leow,et al.  The Role of Arg157Ser in Improving the Compactness and Stability of ARM Lipase , 2012 .

[38]  N. Hogg,et al.  T-cell integrins: more than just sticking points , 2003, Journal of Cell Science.

[39]  Michael L. Dustin,et al.  T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1 , 1989, Nature.

[40]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[41]  A. Christopoulos.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[42]  Gang Liu,et al.  Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents , 2001 .

[43]  P. Bates,et al.  The I Domain of Integrin Leukocyte Function-associated Antigen-1 Is Involved in a Conformational Change Leading to High Affinity Binding to Ligand Intercellular Adhesion Molecule 1 (ICAM-1)* , 1998, The Journal of Biological Chemistry.

[44]  Duncan Poole,et al.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. , 2013, Journal of chemical theory and computation.